Tetraphase Pharmaceuticals Inc (TTPH) SEC Filing 10-K Annual report for the fiscal year ending Saturday, December 31, 2016

Earnings Press Release
10-K Annual Report
10-K YoY Changes
Tetraphase Pharmaceuticals Inc
Ticker: TTPH CIK: 1373707

Exhibit 99.1

LOGO

Tetraphase Pharmaceuticals Reports Fourth Quarter and Full-Year 2016 Financial Results and

Highlights Key 2017 Milestones

–Event-Driven 2017 Includes MAA Filing for IV Eravacycline in Europe and Top-Line Data Readout from IGNITE4 in cIAI –

– Company to Host Conference Call Today, March 8, 2017 at 4:30 p.m. ET –

WATERTOWN, Mass., March 8, 2017 – Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today reported financial results for the fourth quarter and year-ended December 31, 2016, highlighted key milestones for 2017 and provided an overview of recent achievements.

“2016 marked a year of important progress for Tetraphase as we advanced our phase 3 global development program for IV eravacycline with initiation of IGNITE4 in complicated intra-abdominal infections (cIAI), in which enrollment is proceeding well, and the recent commencement of IGNITE3 in complicated urinary tract infections (cUTI),” said Guy Macdonald, President and Chief Executive Officer of Tetraphase. “We have laid the groundwork for an event-driven 2017 and look forward to several important IV eravacycline milestones, including the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for the treatment of cIAI during the second half of the year and top-line data from IGNITE4 during the fourth quarter, which would support a subsequent NDA filing.”

Mr. Macdonald continued, “Beyond IV eravacycline, we are also focused on completing the phase 1 clinical development of oral eravacycline and expect to provide an update during the third quarter of 2017, including next steps toward our goal of delivering the first and only IV-to-oral antibiotic transition therapy for the treatment of MDR gram-negative infections.”

Key Milestones for 2017

•

Submit MAA for IV eravacycline to EMA for the treatment of cIAI – 2H 2017

•

Report top-line data from phase 3 IGNITE4 trial evaluating IV eravacycline in cIAI – 4Q 2017

•

Provide oral eravacycline development program update – 3Q 2017

•

Report phase 1 single-ascending dose data for TP-271 – mid-2017

•

Report phase 1 single-ascending dose data for TP-6076 – mid-2017

•

Initiate phase 1 multiple-ascending dose trials for IV TP-271 and IV TP-6076 – 2017

The following information was filed by Tetraphase Pharmaceuticals Inc (TTPH) on Wednesday, March 8, 2017 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one year to another to evaluate Tetraphase Pharmaceuticals Inc's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ) — *Sample 10-K Year-over-Year (YoY) Comparison*

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were ~~removed~~ , added and changed by Tetraphase Pharmaceuticals Inc.

Continue

Please wait while we load the requested 10-K report or click the link below:

https://last10k.com/sec-filings/report/1373707/000156459017004141/ttph-10k_20161231.htm